Baxter AG and Jerini AG recently announced the progress of their collaborative research program that aims to develop a non-intravenous therapy for the treatment of hemophilia, in which extensive in vitro and in vivo analyses have identified several synthetic lead molecules with promising pharmacological properties.
Hemophilia is a condition where an individual does not produce enough amounts of factor VIII or factor IX protein, which are necessary for blood to effectively clot. People with severe hemophilia if not treated have a greatly reduced life expectancy.
"Using our proprietary technology platform, we continue to make important progress in our collaboration with Baxter, the leader in hemophilia therapy," said Jens Schneider-Mergener, Jerini AG's chief executive officer. "We are encouraged by the identification of these molecules and the evaluation of the potential to treat hemophilia using a non-intravenous therapy with molecules that can be synthetically produced."
Current hemophilia therapies can only be administered intravenously because blood-clotting proteins are large and relatively unstable molecules. Intravenous administration we all know is an invasive and a technically demanding procedure.
However, because of poor distribution or rapid inactivation of the blood-clotting protein molecule in the body, it cannot be administered non-intravenously. With this fact, potential non-intravenous therapy is importantly seeked, one therapy that must be able to reach its target site quickly and effectively without being inactivated in the process.
Source: Baxter News
.jpg)
Comment Preview